Page 4 - Symphony Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Digital Therapeutics Startup Kaia Health Raises $75M to Optimize MSK & COPD Care What You Should Know: – Digital therapeutics company, Kaia Health, has raised $75M Series C round (total: $125M) to expand clinical capabilities and transform the treatment path for Musculoskeletal (MSK) and Chronic obstructive pulmonary disease (COPD) care in the U.S. and Europe. – The Series C round was led by an unnamed leading growth equity fund with support from existing investors, including Optum Ventures, Eurazeo, 3VC, Balderton Capital, Heartcore Capital, Symphony Ventures (investment vehicle of f...

Kaia Health grabs $75M on surging interest in its virtual therapies for chronic pain and COPD New York headquartered Kaia Health, which offers AI-assisted digital therapies via a mobile app for chronic pain related to musculoskeletal (MSK) disorders and for Chronic Obstructive Pulmonary Disease (COPD), has raised a $75 million Series C. The round was led by an unnamed leading growth equity fund with support from existing investors, including Optum Ventures, Eurazeo, 3VC, Balderton Capital, Heartcore Capital, Symphony Ventures (golfer Rory McIlroy’s investment vehicle), and A Round Capital. ...

April 1, 2021 By Bio-IT World Staff April 1, 2021 | New investment funds for late-stage companies and public health. Next-gen genomic medicines and single-cell multiomics get cash, and PatientsLikeMe raises a new round of funding to expand.   $969M Investment Fund for Early to Late-Stage Companies Foresite Capital, a multi-stage healthcare and life sciences investment firm, has announced its fifth and largest fundraise with $969 million in capital commitments, significantly oversubscribed above its original target. The offering comprises Foresite Capital Fund V, L.P. and Foresit...